BCR and B-cell chronic lymphocytic leukemia: The synergistic combination of macitentan with the BTK inhibitor ibrutinib completely nullified BCR-mediated survival and intracellular signaling, indicating the convergence of BCR and ET receptors downstream pathways in CLL cells (Figures 3B-3C).